Cangen Biotechnologies

Cangen Biotechnologies was a molecular diagnostics company specializing in the early detection and monitoring of cancer through non-invasive testing. The company's core technology, Microsatellite Analysis (MSA), was designed to identify genetic alterations in bodily fluids such as urine, sputum, and blood. Cangen focused on high-incidence cancers including bladder, lung, and head and neck cancers, leveraging intellectual property licensed from Johns Hopkins University. Their approach aimed to provide high-sensitivity screening solutions to improve patient outcomes through earlier intervention and recurrence monitoring. Although the company successfully advanced several diagnostic candidates into clinical validation and limited commercial use, it is no longer active.